INOVIO to Present at Upcoming Scientific Conferences

INOVIO to Present at Upcoming Scientific Conferences

April 09, 2025 | Last Trade: US$1.73 0.03 -1.70

PLYMOUTH MEETING, Pa., April 9, 2025 /PRNewswire/ -- INOVIO (NASDAQ:INO), a biotechnology company focused on developing and commercializing DNA medicines to help treat and protect people from HPV-related diseases, cancer, and infectious diseases, today announced that it will highlight key data associated with its lead candidate, INO-3107, at several upcoming conferences, including an opportunity to join other leading voices at the inaugural National HPV Conference. INOVIO will also discuss its novel DNA-encoded monoclonal antibody technology at a preconference workshop at the World Vaccine Congress.

National HPV Conference (Indianapolis, IN)

April 15:

Oral presentation: DNA Immunotherapy (INO-3107) Results in a 72% Overall Response Rate in Year 1 for Treatment of Recurrent Respiratory Papillomatosis Caused by HPV-6 & 11
Panel: Recurrent Respiratory Papillomatosis: Lessons Learned, Clinical Advances and Patient Experiences – Moderated by Kim McClellan, RRP Foundation President

World Vaccine Congress (Washington, DC)

April 21:

Oral presentation: A New Frontier in mAb Therapeutics: DNA-Encoded Monoclonal Antibodies (DMAb™) as Next Gen DNA Medicine

April 23:

Oral presentation: DNA Immunotherapeutics in the Treatment of Cancers and Virally-Mediated Diseases

Festival of Biologics (San Diego, CA)

April 23:

Oral presentation: Advancing DNA Medicine: INO-3107 for Recurrent Respiratory Papillomatosis

Available abstracts will be shared on INOVIO's website following presentations.

About INOVIO

INOVIO is a biotechnology company focused on developing and commercializing DNA medicines to help treat and protect people from HPV-related diseases, cancer, and infectious diseases. INOVIO's technology optimizes the design and delivery of innovative DNA medicines that teach the body to manufacture its own disease-fighting tools. For more information, visit www.inovio.com.

Contacts

Media: Jennie Willson, (267) 429-8567, This email address is being protected from spambots. You need JavaScript enabled to view it.
Investors: Peter Vozzo - ICR Healthcare, (443) 213-0505, This email address is being protected from spambots. You need JavaScript enabled to view it.

Stock Quote

Last Trade:	US$1.73
Daily Change:	-0.03 -1.70
Daily Volume:	99,118
Market Cap:	US$62.450M

March 18, 2025 INOVIO Reports Fourth Quarter and Full Year 2024 Financial Results and Operational Highlights March 13, 2025 INOVIO Announces Promising Interim Results from Ongoing Proof-of-Concept Clinical Trial of DNA-Encoded Monoclonal Antibodies (DMAbs) for COVID-19 February 12, 2025 INOVIO: Clinical and Immunological Results from Phase 1/2 Study of INO-3107 as a Treatment for Recurrent Respiratory Papillomatosis Published in Nature Communications February 10, 2025 INOVIO: Immune Response Data for INO-3107 to be Presented as a Poster at American Association for Cancer Research Immuno-Oncology (AACR-IO) Conference December 12, 2024 INOVIO Announces Proposed Public Offering LOAD MORE NEWS

Featured Stock

Chimerix is on a mission to develop medicines that meaningfully improve and extend the lives of patients facing deadly diseases. The company is devoted to filling gaps in the treatment paradigm. Chimerix’s most advanced clinical-stage program is in development for H3 K27M-mutant glioma....

CLICK TO LEARN MORE

Featured Stock

C4 Therapeutics is pioneering a new class of small-molecule drugs that selectively destroy disease-causing proteins via degradation using the innate machinery of the cell. This targeted protein degradation approach offers advantages over traditional drugs, including the potential to treat a wider range of diseases...

CLICK TO LEARN MORE